Table 5.
Individual and combined effects of SNPs from our susceptibility pathways on lung cancer risk in the meta-analysis of Discovery Cohorts
| Univariate analysis | Multivariate analysis* | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| OR | L95 | U95 | P | P_trend | OR | L95 | U95 | P | P_trend | ||
| CHRNA3 | |||||||||||
| rs1051730 | 0 | 1 | 1.29E-25 | 2.68E-24 | |||||||
| 1 | 1.31 | 1.21 | 1.43 | 3.46E-10 | 1.32 | 1.21 | 1.44 | 1.23E-09 | |||
| 2 | 1.86 | 1.65 | 2.09 | 8.80E-25 | 1.89 | 1.67 | 2.14 | 7.44E-24 | |||
| CHRNB4 | |||||||||||
| rs6495309 | 0 | 1 | 2.35E-12 | 4.56E-11 | |||||||
| 1 | 1.22 | 1 | 1.5 | 0.05 | 1.21 | 0.98 | 1.49 | 0.08 | |||
| 2 | 1.58 | 1.3 | 1.93 | 5.21E-06 | 1.56 | 1.27 | 1.91 | 2.67E-05 | |||
| KCNJ4 | |||||||||||
| rs138396 | 0 | 1 | 0.06 | 0.04 | |||||||
| 1 | 1 | 0.91 | 1.09 | 0.94 | 1.01 | 0.92 | 1.1 | 0.89 | |||
| 2 | 1.13 | 1.01 | 1.26 | 0.03 | 1.15 | 1.02 | 1.29 | 0.02 | |||
| SCN2B | |||||||||||
| rs7944321 | 0 | 1 | 0.07 | 0.14 | |||||||
| 1 | 1.07 | 0.98 | 1.16 | 0.13 | 1.06 | 0.97 | 1.15 | 0.19 | |||
| 2 | 1.12 | 0.94 | 1.34 | 0.22 | 1.09 | 0.91 | 1.32 | 0.35 | |||
| neuroactive ligand receptor interaction pathway | |||||||||||
| (CHRNA3 rs1051730 and CHRNB4 rs6495309) | |||||||||||
| 0-1 | 1 | 2.80E-26 | 1 | 1.55E-24 | |||||||
| 2 | 1.32 | 1.18 | 1.47 | 8.45E-07 | 1.32 | 1.18 | 1.48 | 1.82E-06 | |||
| 3 | 1.48 | 1.32 | 1.65 | 4.94E-12 | 1.47 | 1.31 | 1.65 | 6.14E-11 | |||
| 4 | 2.04 | 1.79 | 2.33 | 2.22E-26 | 2.07 | 1.8 | 2.38 | 4.99E-25 | |||
| gated channel activity term | |||||||||||
| (CHRNA3 rs1051730, CHRNB4 rs6495309, KCNJ4 rs138396 and SCN2B rs7944321) | |||||||||||
| 0-1 | 1 | 4.39E-19 | 2.46E-18 | ||||||||
| 2-3 | 1.29 | 1.08 | 1.53 | 5.50E-03 | 1.3 | 1.08 | 1.56 | 5.50E-03 | |||
| 4-5 | 1.6 | 1.34 | 1.9 | 1.84E-07 | 1.63 | 1.36 | 1.96 | 1.65E-07 | |||
| 6-8 | 2.15 | 1.74 | 2.65 | 9.31E-13 | 2.17 | 1.74 | 2.7 | 4.01E-12 | |||
*Adjusted by age sex smoke status in the Logistic Models.